Galmed Pharmaceuticals Ltd

(NASDAQ:GLMD)

Latest On Galmed Pharmaceuticals Ltd (GLMD):

Date/Time Type Description Signal Details
2023-01-04 19:45 ESTNewsGalmed rises 17% on positive data from NASH treatment trialN/A
2022-08-04 11:33 ESTNewsGalmed GAAP EPS of -$0.15 beats by $0.09N/A
2022-06-18 07:35 ESTNewsGalmed Pharma receives non-compliance letter from NasdaqN/A
2022-05-19 03:05 ESTNewsGalmed Pharmaceuticals shares fall after downgrade by Raymond James analystN/A
2022-05-18 07:26 ESTNewsGalmed GAAP EPS of -$0.24 beats by $0.08N/A
2022-05-04 07:02 ESTNewsGalmed slips further as H.C. Wainwright cuts rating on uncertainty to NASH trialN/A
2022-05-02 20:41 ESTNewsGalmed GAAP EPS of -$0.30 in-lineN/A
2022-05-02 20:40 ESTNewsGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call TranscriptN/A
2022-01-11 12:41 ESTNewsGalmed gains 5% after securing three new U.S. patents for Aramchol and meglumine saltN/A
2021-11-20 09:22 ESTNewsGalmed Pharmaceuticals (GLMD) Investor presentation - SlideshowN/A
2021-11-09 09:38 ESTNewsGalmed Pharmaceuticals Ltd. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-09 09:37 ESTNewsGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-08 12:20 ESTNewsGalmed EPS beats by $0.67N/A
2021-11-01 20:04 ESTNewsGalmed posts initial results from late-stage Aramchol NASH and liver fibrosis trialN/A
2021-08-10 04:42 ESTNewsGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 03:42 ESTNewsGalmed EPS beats by $0.05N/A
2021-08-02 17:27 ESTNewsGalmed Pharma jumps 8% on FDA green light to use Aramchol Meglumine in late-stage ARMOR studyN/A
2021-05-03 23:15 ESTNewsGalmed gets greenlight for late-stage Aramchol NASH trial in ChinaN/A
2021-03-18 19:33 ESTNewsGalmed EPS misses by $0.11N/A
2021-03-18 19:33 ESTNewsGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call TranscriptN/A
2021-02-16 09:52 ESTNewsGalmed Pharma slips 4% on launch of share offeringN/A
2021-02-16 09:51 ESTNewsGalmed Pharmaceuticals prices $10M capital raiseN/A
2021-01-12 11:48 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.4 to $17.8.Neutral
2020-11-26 20:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 12:03 ESTAnalyst RatingThe Analyst Target Price has decreased from $19.4 to $18.4.Neutral
2020-11-17 19:58 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 04:08 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 12:07 ESTEarnings EstimateAn EPS average of -$0.37 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 12:07 ESTAnalyst RatingThe Analyst Target Price has decreased from $19.6 to $19.4.Neutral
2020-11-13 00:13 ESTNewsGalmed EPS misses by $0.02N/A
2020-11-13 00:11 ESTNewsGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 15:57 ESTFinancialsCompany financials have been released.Neutral
2020-10-08 09:02 ESTAnalyst RatingThe Analyst Target Price has increased from $17.67 to $19.6.Buy
2020-09-26 12:53 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:00 ESTFinancialsCompany financials have been released.Neutral
2020-09-09 20:48 ESTNewsGalmed collaborates with Gannex Pharma for development programs in NASHN/A
2020-09-08 20:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $19.86 to $17.67.Neutral
2020-08-14 08:57 ESTFinancialsCompany financials have been released.Neutral
2020-08-09 14:24 ESTNewsGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-08 12:49 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 17:58 ESTNewsGalmed EPS beats by $0.06N/A
2020-07-31 01:07 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:09 ESTFinancialsCompany financials have been released.Neutral
2020-07-13 12:42 ESTAnalyst RatingThe Analyst Target Price has decreased from $20.5 to $19.86.Neutral
2020-07-09 08:51 ESTFinancialsCompany financials have been released.Neutral
2020-06-26 08:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 04:53 ESTFinancialsCompany financials have been released.Neutral
2020-06-10 08:44 ESTAnalyst RatingThe Analyst Target Price has increased from $20.06 to $20.5.Buy
2020-06-02 08:46 ESTEarnings EstimateAn EPS average of -$0.35 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-02 08:46 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.94 to $20.06.Neutral

About Galmed Pharmaceuticals Ltd (GLMD):

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.

GLMD Quotes by TradingView

See Advanced Chart

General

  • Name Galmed Pharmaceuticals Ltd
  • Symbol GLMD
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 17
  • Fiscal Year EndDecember
  • IPO Date2014-03-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.galmedpharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 1.74
  • Enterprise Value EBITDA 0.13
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.32
  • Return on Assets -25%
  • Return on Equity -41%
  • Earnings Per Share -$0.59
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 81.86 million
  • EBITDA -13835000
  • Analyst Target Price $17.8
  • Book Value Per Share $2.52
View More

Share Statistics

  • Shares Outstanding 23.52 million
  • Shares Float 13.28 million
  • % Held by Insiders 1732%
  • % Held by Institutions 32.54%
  • Shares Short 192925
  • Shares Short Prior Month 39442
  • Short Ratio 0.28
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 2.21
  • 52 Week High $6.2
  • 52 Week Low $2.96
  • 50 Day Moving Average 4.08
  • 200 Day Moving Average 3.72
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Galmed Pharmaceuticals Ltd (GLMD) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Galmed Pharmaceuticals Ltd (GLMD) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$N/A-$0.32-$0.3815.05%
2020-06-302020-08-06$N/A-$0.26-$0.3219.75%
2020-03-312020-05-14$N/A-$0.29-$0.3516.67%
2019-12-312020-03-12$N/A-$0.39-$0.35-11.81%
2019-09-302019-11-06$N/A-$0.21-$0.3131.31%
2019-06-302019-08-05$N/A-$0.20-$0.227.28%
2019-03-312019-05-07$N/A-$0.17-$0.2117.91%
2018-12-312019-03-13$538000-$0.18-$0.13-38.46%
2018-09-302018-11-05$1.5 million-$0.05-$0.1464.29%
2018-06-302018-08-02$270000-$0.17-$0.16-7.19%
2018-03-312018-05-09$268000-$0.17-$0.2326.09%
2017-12-312018-03-13$274000-$0.27-$0.22-21.62%
2017-09-302017-11-09$273000-$0.23-$0.2713.76%
2017-06-302017-07-31$270000-$0.22-$0.3333.33%
2017-03-312017-05-15$268000-$0.26-$0.3832.03%
2016-12-312017-03-23$274000-$0.40-$0.30-32.45%
2016-09-302016-11-07$193000-$0.34-$0.3912.82%
2016-06-302016-08-03$N/A-$0.39-$0.35-12.72%
2016-03-312016-05-16$N/A-$0.36-$0.34-5.88%
2015-12-312016-03-22$N/A-$0.29-$0.28-4.5%
2015-09-302015-11-09$N/A-$0.23-$0.2920.69%
2015-06-302015-08-13$N/A-$0.21-$0.2516%
2015-03-312015-05-13$N/A-$0.22-$0.3638.89%
2014-12-312015-03-31$N/A-$0.15-$0.3557.14%
2014-09-302014-11-12$N/A-$0.31-$0.3716.22%
2014-06-302014-07-25$N/A-$0.15-$0.3557.14%
2014-03-312014-05-14$N/A-$0.27-$0.296.9%

Galmed Pharmaceuticals Ltd (GLMD) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development 6.54 million N/A 5.55 million 7.36 million 4.05 million
Income Before Tax -6.91 million N/A -6.06 million -8.29 million -4.51 million
Selling General Administrative 1.05 million N/A 912000 1.27 million 953000
Gross Profit N/A N/A N/A N/A N/A
Ebit -7.58 million N/A -6.45 million -8.63 million -5.01 million
Operating Income -7.59 million N/A -6.46 million -8.63 million -5.01 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 342000 493000
Net Income From Continuing Operations -6.91 million N/A -6.06 million -8.29 million -4.51 million
Net Income Applicable to Common Shares -6.91 million -5.53 million N/A -8.29 million -4.51 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A 3.91 million 1.77 million -3.61 million
Change to Liabilities 1.28 million -1.6 million N/A 3.26 million 164000
Total Cash Flow from Investing Activities 16 million -1.51 million N/A 1.77 million -3.62 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 61000 48000 N/A
Change to Operating Activities 101000 230000 N/A 112000 96000
Change in Cash N/A N/A -2.61 million -2.25 million -7.49 million
Total Cash from Operating Activities -5.61 million -6.25 million -6.59 million -4.07 million -3.87 million
Depreciation N/A N/A 10000 8000 9000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 71000 -193000
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income -114000 507000 N/A 772000 570000
Capital Expenditures N/A N/A N/A 3000 5000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 6.34 million 7.29 million 3.93 million
Total Stockholder Equity N/A N/A 64.1 million 69.85 million 77.42 million
Other Current Liabilities N/A N/A N/A 935000 798000
Total Assets 59.95 million N/A 70.44 million 77.14 million 81.35 million
Common Stock N/A 58000 N/A 58000 58000
Other Current Assets N/A N/A N/A 112000 N/A
Retained Earnings N/A -118.53 million -113 million -106.94 million -98.65 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash N/A N/A 13.32 million 15.93 million 18.29 million
Total Current Liabilities N/A N/A 6.03 million 6.93 million 3.54 million
Other Stockholder Equity N/A 498000 N/A 35000 52000
Property, Plant & Equipment N/A 638000 N/A 709000 724000
Total Current Assets N/A N/A 69.79 million 76.43 million 80.63 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets N/A 59.88 million N/A 69.85 million 77.42 million
Short Term Investments N/A N/A 55.57 million 59.56 million 61.44 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable N/A N/A 5.33 million 6 million 2.74 million

Galmed Pharmaceuticals Ltd (GLMD) Chart:

Galmed Pharmaceuticals Ltd (GLMD) News:

Below you will find a list of latest news for Galmed Pharmaceuticals Ltd (GLMD) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Galmed Pharmaceuticals Ltd (GLMD) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest GLMD Trades:

Date Shares Price
Jun 13, 2022 4:27 PM EST56$0.5192
Jun 13, 2022 5:42 PM EST100$0.5002
Jun 13, 2022 5:42 PM EST1444$0.5002
Jun 13, 2022 7:49 PM EST50$0.4902

Galmed Pharmaceuticals Ltd (GLMD) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920075231/0001104659-20-075231-index.htm
2018-04-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1595353/000000000018009868/0000000000-18-009868-index.htm
2018-04-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000092189518001345/0000921895-18-001345-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000092189519000480/0000921895-19-000480-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000092189520000543/0000921895-20-000543-index.htm
2017-12-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000101359417000827/0001013594-17-000827-index.htm
2018-06-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000101359418000394/0001013594-18-000394-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000101359420000134/0001013594-20-000134-index.htm
2020-07-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000107997320000628/0001079973-20-000628-index.htm
2019-10-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465919058113/0001104659-19-058113-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465919060261/0001104659-19-060261-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000110465920020233/0001104659-20-020233-index.htm
2020-03-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920032151/0001104659-20-032151-index.htm
2020-03-1220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1595353/000110465920032166/0001104659-20-032166-index.htm
2020-05-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920061141/0001104659-20-061141-index.htm
2020-05-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1595353/000110465920062691/0001104659-20-062691-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920062710/0001104659-20-062710-index.htm
2020-05-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920063209/0001104659-20-063209-index.htm
2020-05-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920064790/0001104659-20-064790-index.htm
2020-06-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920075231/0001104659-20-075231-index.htm
2020-07-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920082108/0001104659-20-082108-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920091117/0001104659-20-091117-index.htm
2020-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920095583/0001104659-20-095583-index.htm
2020-09-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000110465920103303/0001104659-20-103303-index.htm
2016-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416110688/0001144204-16-110688-index.htm
2016-07-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416114813/0001144204-16-114813-index.htm
2016-08-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416115467/0001144204-16-115467-index.htm
2016-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416116076/0001144204-16-116076-index.htm
2016-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416123158/0001144204-16-123158-index.htm
2016-09-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416124839/0001144204-16-124839-index.htm
2016-09-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416125902/0001144204-16-125902-index.htm
2016-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420416131862/0001144204-16-131862-index.htm
2017-01-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417001221/0001144204-17-001221-index.htm
2017-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000114420417007899/0001144204-17-007899-index.htm
2017-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000114420417007901/0001144204-17-007901-index.htm
2017-03-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417014739/0001144204-17-014739-index.htm
2017-03-2320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/0001144204-17-016148-index.htm
2017-03-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417016149/0001144204-17-016149-index.htm
2017-04-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417019055/0001144204-17-019055-index.htm
2017-04-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417022635/0001144204-17-022635-index.htm
2017-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417027050/0001144204-17-027050-index.htm
2017-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417031606/0001144204-17-031606-index.htm
2017-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417031616/0001144204-17-031616-index.htm
2017-06-236-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417033829/0001144204-17-033829-index.htm
2017-06-2320-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1595353/000114420417033833/0001144204-17-033833-index.htm
2017-06-2320-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1595353/000114420417033835/0001144204-17-033835-index.htm
2017-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417039116/0001144204-17-039116-index.htm
2017-08-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417040429/0001144204-17-040429-index.htm
2017-08-04POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/1595353/000114420417040470/0001144204-17-040470-index.htm
2017-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1595353/000114420417040690/0001144204-17-040690-index.htm
2017-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417040692/0001144204-17-040692-index.htm
2017-08-15DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1595353/000114420417043518/0001144204-17-043518-index.htm
2017-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417051431/0001144204-17-051431-index.htm
2017-11-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417057429/0001144204-17-057429-index.htm
2017-12-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420417065092/0001144204-17-065092-index.htm
2017-12-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1595353/000114420417065093/0001144204-17-065093-index.htm
2018-01-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418000046/0001144204-18-000046-index.htm
2018-01-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418000341/0001144204-18-000341-index.htm
2018-01-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000114420418004033/0001144204-18-004033-index.htm
2018-01-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000114420418004035/0001144204-18-004035-index.htm
2018-02-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418006103/0001144204-18-006103-index.htm
2018-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418008259/0001144204-18-008259-index.htm
2018-03-1320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1595353/000114420418014234/0001144204-18-014234-index.htm
2018-03-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418014235/0001144204-18-014235-index.htm
2018-03-26F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1595353/000114420418016920/0001144204-18-016920-index.htm
2018-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1595353/000114420418018519/0001144204-18-018519-index.htm
2018-04-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418018816/0001144204-18-018816-index.htm
2018-04-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1595353/000114420418019239/0001144204-18-019239-index.htm
2018-04-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418019242/0001144204-18-019242-index.htm
2018-05-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418026334/0001144204-18-026334-index.htm
2018-06-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418033830/0001144204-18-033830-index.htm
2018-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/0001144204-18-034494-index.htm
2018-06-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1595353/000114420418034496/0001144204-18-034496-index.htm
2018-06-18FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1595353/000114420418034498/0001144204-18-034498-index.htm
2018-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418035168/0001144204-18-035168-index.htm
2018-07-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418039024/0001144204-18-039024-index.htm
2018-08-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418041524/0001144204-18-041524-index.htm
2018-08-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418047349/0001144204-18-047349-index.htm
2018-09-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1595353/000114420418050116/0001144204-18-050116-index.htm
2018-10-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418054037/0001144204-18-054037-index.htm
2018-10-29S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1595353/000114420418055835/0001144204-18-055835-index.htm
2018-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418057165/0001144204-18-057165-index.htm
2018-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418059978/0001144204-18-059978-index.htm
2018-12-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420418066157/0001144204-18-066157-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000114420419006274/0001144204-19-006274-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1595353/000114420419008145/0001144204-19-008145-index.htm
2019-03-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419013397/0001144204-19-013397-index.htm
2019-03-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419013598/0001144204-19-013598-index.htm
2019-03-1320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/0001144204-19-013601-index.htm
2019-04-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419018194/0001144204-19-018194-index.htm
2019-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419018741/0001144204-19-018741-index.htm
2019-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419024033/0001144204-19-024033-index.htm
2019-05-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419025619/0001144204-19-025619-index.htm
2019-08-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419037537/0001144204-19-037537-index.htm
2019-09-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1595353/000114420419045976/0001144204-19-045976-index.htm
2018-06-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1595353/000157104918000363/0001571049-18-000363-index.htm
2018-04-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1595353/999999999518000736/9999999995-18-000736-index.htm